Tusk Therapeutics to be acquired by Roche

Tusk Therapeutics Ltd has been acquired by Roche. Tusk was founded in 2014 by Droia Oncology Ventures, Tusk’s majority shareholder. Under the terms of...

PharmaDoctor and Star enter into a strategic partnership

PharmaDoctor (owned by Escripts Marketing Ltd), and Star (part of the Uniphar Group), are pleased to announce a strategic partnership between the two companies...

Novo Nordisk acquires Ziylo to accelerate glucose responsive insulin

Ziylo and Novo Nordisk have announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based...

Syneos Health acquires advisory & operational solutions provider Kinapse

Syneos Health, Inc. a biopharmaceutical solutions organisation, has announced the acquisition of Kinapse, a market leading advisory and operational solutions provider to the global...

Almirall acquires US medical dermatology portfolio from Allergan

Almirall, S.A. (ALM) has announced the acquisition of a portfolio of five products from Allergan’s Medical Dermatology unit in the United States for $500...

UDG Healthcare acquire Create NYC and SmartAnalyst

UDG Healthcare plc, an international healthcare services provider, is pleased to announce the acquisition of Create NYC, a New York-based disruptive creative communications agency...

Laekna acquires worldwide rights to two oncology assets

Laekna Inc., a biotechnology company headquartered in Shanghai, announced the signing of an agreement with Novartis Pharma for exclusive global rights to develop and...

LEO Pharma to acquire Bayer’s dermatology unit

LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription...

AstraZeneca sells rights for Atacand to Cheplapharm

AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe...

NanoGenics acquired to advance gene therapy

The Scottish Biotech company Ryboquin, announces the acquisition of Nanogenic Solutions, to form a new product and platform company, Nanogenics Limited. The combined company,...

Latest articles

Image of a man pumping air into a pund symbol to indicate drug firms admitting to colluding to keep up prices of antidepressants

Drug firms admit to colluding to keep up prices of antidepressants

Drug firms admit to colluding in order to keep up prices of antidepressants according to the Competition and Markets Authority (CMA). Two suppliers of the...
Licensing status of Avastin updated by MHRA

Licensing status of Avastin updated by MHRA

The licensing status of Avastin has been updated by the Medicines and Healthcare products Regulatory Agency (MHRA). The update concerns the licensing status of Avastin (bevacizumab)...
PM Society Digital Award Winners

PM Society Digital Award Winners 2019

Thursday 19th September saw the tenth PM Society Digital Awards take place at The Brewery in London. Around 500 guests sat down to dinner...

Popular articles

pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
Licensing status of Avastin updated by MHRA

Licensing status of Avastin updated by MHRA

The licensing status of Avastin has been updated by the Medicines and Healthcare products Regulatory Agency (MHRA). The update concerns the licensing status of Avastin (bevacizumab)...
PM Society Digital Award Winners

PM Society Digital Award Winners 2019

Thursday 19th September saw the tenth PM Society Digital Awards take place at The Brewery in London. Around 500 guests sat down to dinner...
image of a hospital and ambulance showing poor diabetes control costs the NHS £3bn in avoidable treatment

Poor diabetes control costs the NHS £3bn in avoidable treatment

New research finds that poor diabetes control costs the NHS £3bn in potentially avoidable hospital treatment in England. The findings, being presented at this year’s...
Image of a man pumping air into a pund symbol to indicate drug firms admitting to colluding to keep up prices of antidepressants

Drug firms admit to colluding to keep up prices of antidepressants

Drug firms admit to colluding in order to keep up prices of antidepressants according to the Competition and Markets Authority (CMA). Two suppliers of the...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription